GlassScriptPhysician profile
Elza B Robinson
NPI 1346235587
$1,611.68
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $403 · 2021: $659.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $274.81 | 2021 | |
| Abbvie INC. | $264.98 | 2019-2021 | |
| Lupin INC. | $246.29 | 2019-2021 | |
| Amgen INC. | $173.06 | 2020-2021 | |
| Pfizer INC. | $161.76 | 2019-2021 | |
| Avion Pharmaceuticals | $98.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $77.77 | 2019-2020 | |
| Lilly USA, LLC | $68.25 | 2019-2020 | |
| Evofem Biosciences, INC. | $66.23 | 2020-2021 | |
| Therapeuticsmd, INC. | $48.76 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $33.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.02 | 2021 | |
| Merck Sharp & Dohme LLC | $17.72 | 2020 | |
| Exeltis, USA INC. | $14.70 | 2021 | |
| Duchesnay USA Incorporated | $13.24 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.33 | 2020 | |
| Aspira Women'S Health INC | $11.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elza Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.